In this study, we focused on the TTP488-mediated alleviation of AD injury, which occurs via the inhibition of NLRP1 inflammasome activation, using lipopolysaccharide (LPS) and an NLRP1 overexpression lentivirus (oeNLRP1) to suppress the effects of TTP488. The gene discussed is NLRP1; the disease is Alzheimer disease.